Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation

Drug Metabolism Reviews

Volumn 31, Issue 2, 1999, Pages 381-392

  Kleeberg, Ullrich ^a   Frötschl, Roland ^b   Krusekopf, Solveigh ^c   Brockmöller, Jürgen ^b   Roots, Ivar ^b   Ruckpaul, Klaus ^c   Hildebrandt, Alfred G ^a  

^a Fed Inst Drugs and Med Devices   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Benzimidazoles; Cell lines (HEPG2, HUH7, HELA); Cytochromes (CYP1A, CYP1B1); H K ATPase inhibitors; Induction; Transcription (RNA polymerase, mRNA)

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CYTOCHROME P450;

CELL LINE; CELL SPECIFICITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE RESPONSE; DRUG INDICATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INDUCTION; EUROPEAN UNION; HEPATOMA CELL; HUMAN; HUMAN CELL; LYMPHOCYTE; NORMAL HUMAN; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

BENZIMIDAZOLES; CYTOCHROME P-450 CYP1A1; DRUG AND NARCOTIC CONTROL; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 0345211501     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101925     Document Type: Conference Paper

References (16)

1. T. Andersson, Clin. Pharmacokinet., 31, 9-28 (1996).
2. G. Sachs, J. M. Shin, C. Briving, B. Wallmark, and S. Hersey, Annu. Rev. Pharmacol. Toxicol., 35, 277-305 (1995).
3. M. L. Schwartzman and N. G. Abraham, Methods Enzymol., 187, 372-384 (1990).
4. A. B. Okey, D. S. Riddick, and P. A. Harper, Trends Pharmacol. Sci., 15, 226-232 (1994).
5. A. B. Okey, D. S. Riddick, and P. A. Harper, Toxicol. Lett., 70, 1-22 (1994).
6. D. L. Alexander, S. E. Eltom, and C. R. Jefcoate, Cancer Res., 57, 4498-4506 (1997).
7. T. Shimada, C. L. Hayes, H. Yamazaki, S. Amin, S. S. Hecht, F. P. Guengerich, and T. R. Sutter, Cancer Res., 56, 2979-2984 (1996).
8. U. Kleeberg, J. Szeberenyi, P. Juhasz, A. Tigyi, and W. Klinger, Biochem. Pharmacol., 31, 1063-1067 (1982).
9. S. Krusekopf, U. Kleeberg, A. G. Hildebrandt, and K. Ruckpaul, Xenobiotica, 27, 1-9 (1997).
10. R. Curi-Pedrosa, M. Daujat, L. Picard, J. C. Ourlin, P. Clair, L. Gervot, P. Lesca, J. Domergue, H. Joyeux, G. Fourtanier, and P. Maurel, J. Pharmacol. Exp. Ther., 269, 384-392 (1994).
11. J. P. Whitlock, C. H. Chichester, R. M. Begood, S. T. Okino, H. P. Ko, Q. Ma, L. Q. Dong, H. Li, and R. Clarke-Katzenberg, Drug Metab. Rev., 29, 1107-1127 (1997).
12. T. R. Sutter, Y. M. Tang, C. L. Hayes, Y. Y. Wo, E. W. Jabs, X. Li, H. Yin, C. W. Cody, and W. F. Greenlee, J. Biol. Chem., 269, 13092-13099 (1994).
13. R. Frötschl, U. Kleeberg, A. G. Hildebrandt, I. Roots, and J. Brockmöller, Anal. Biochem., 242, 280-282 (1996).
14. F.-L. Yu, Biochem. Biophys. Acta, 395, 329-336 (1975).
15. T. Higashinakagawa, M. Muramatsu, and H. Sugano, Exp. Cell Res., 71, 65-74 (1972).
16. R. A. Jungmann and E. G. Kranias, Int. J. Biochem., 8, 819-830 (1977).